Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and Exchange ...
IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...
as analysts started to talk about a blockbuster sales opportunity for the selective myostatin inhibitor. SMA is a genetic disorder that can cause rapid and irreversible loss of motor neurons ...
LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...
Providing additional update on the Phase 2 TROPOS trial on Wednesday, biopharmaceutical company Keros Therapeutics, Inc. (KROS) ...
Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...
Barclays PLC grew its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 103.4% in the 3rd quarter ...
an investigational selective inhibitor of latent TGFβ1 activation, in patients with advanced solid tumors at the Society for I CAMBRIDGE, Mass., October 22, 2024--Scholar Rock Holding Corporation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback